Hansjakob Furrer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3053895/publications.pdf

Version: 2024-02-01

317 papers	19,809 citations	10351 72 h-index	14156 128 g-index
333 all docs	333 docs citations	333 times ranked	16563 citing authors

#	Article	IF	Citations
1	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	0.6	1,056
2	Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet, The, 1999, 353, 863-868.	6.3	894
3	Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2010, 10, 251-261.	4.6	638
4	Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet, The, 2002, 359, 30-36.	6.3	635
5	Morbidity and Aging in HIV-Infected Persons: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2011, 53, 1130-1139.	2.9	525
6	Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2007, 7, 607-613.	4.6	450
7	AIDS-Related Opportunistic Illnesses Occurring After Initiation of Potent Antiretroviral Therapy. JAMA - Journal of the American Medical Association, 1999, 282, 2220.	3.8	416
8	Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenetics and Genomics, 2005, 15, 1-5.	0.7	355
9	CD4 T-Lymphocyte Recovery in Individuals With Advanced HIV-1 Infection Receiving Potent Antiretroviral Therapy for 4 Years<subtitle>The Swiss HIV Cohort Study</subtitle>. Archives of Internal Medicine, 2003, 163, 2187.	4.3	344
10	Cohort Profile: The Swiss HIV Cohort Study. International Journal of Epidemiology, 2010, 39, 1179-1189.	0.9	322
11	Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, The, 2001, 358, 1322-1327.	6.3	317
12	Characteristics, Determinants, and Clinical Relevance of CD4 T Cell Recovery to <500 Cells/ÂL in HIV Type 1--Infected Individuals Receiving Potent Antiretroviral Therapy. Clinical Infectious Diseases, 2005, 41, 361-372.	2.9	285
13	Discontinuation of Primary Prophylaxis againstPneumocystis cariniiPneumonia in HIV-1â€“Infected Adults Treated with Combination Antiretroviral Therapy. New England Journal of Medicine, 1999, 340, 1301-1306.	13.9	271
14	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
15	CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet, The, 2006, 368, 459-465.	6.3	233
16	Factors Associated with the Incidence of Type 2 Diabetes Mellitus in HIV-Infected Participants in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2007, 45, 111-119.	2.9	233
17	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clinical Infectious Diseases, 2012, 55, 1408-1416.	2.9	225
18	Unsafe Sex and Increased Incidence of Hepatitis C Virus Infection among HIV-Infected Men Who Have Sex with Men: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2005, 41, 395-402.	2.9	203

#	Article	IF	Citations
19	Life expectancy in HIV-positive persons in Switzerland. Aids, 2017, 31, 427-436.	1.0	193
20	Gilbert Syndrome and the Development of Antiretroviral Therapyâ€“Associated Hyperbilirubinemia. Journal of Infectious Diseases, 2005, 192, 1381-1386.	1.9	182
21	Prevalence of comedications and effect of potential drugâ€“drug interactions in the Swiss HIV Cohort Study. Antiviral Therapy, 2010, 15, 413-423.	0.6	172
22	Molecular Epidemiology Reveals Longâ€Term Changes in HIV Type 1 Subtype B Transmission in Switzerland. Journal of Infectious Diseases, 2010, 201, 1488-1497.	1.9	172
23	Correlates of Self-Reported Nonadherence to Antiretroviral Therapy in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 385-392.	0.9	156
24	Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy. New England Journal of Medicine, 2001, 344, 168-174.	13.9	155
25	A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection. Archives of Internal Medicine, 2003, 163, 1220.	4.3	153
26	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Medicine, 2012, 9, e1001194.	3.9	145
27	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
28	In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenetics and Genomics, 2009, 19, 300-309.	0.7	133
29	A Randomized Trial of Simplified Maintenance Therapy with Abacavir, Lamivudine, and Zidovudine in Human Immunodeficiency Virus Infection. Journal of Infectious Diseases, 2002, 185, 1251-1260.	1.9	132
30	Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology, 2009, 49, 1069-1082.	3.6	131
31	Ageing with HIV: medication use and risk for potential drug-drug interactions. Journal of Antimicrobial Chemotherapy, 2011, 66, 2107-2111.	1.3	131
32	Treatment Modification in Human Immunodeficiency Virusâ€“Infected Individuals Starting Combination Antiretroviral Therapy Between 2005 and 2008. Archives of Internal Medicine, 2010, 170, 57.	4.3	127
33	Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Aids, 2008, 22, 301-306.	1.0	124
34	Safe Interruption of Maintenance Therapy against Previous Infection with Four Common HIV-Associated Opportunistic Pathogens during Potent Antiretroviral Therapy. Annals of Internal Medicine, 2002, 137, 239.	2.0	122
35	Immunogenicity and Safety of Yellow Fever Vaccination for 102 HIVâ€Infected Patients. Clinical Infectious Diseases, 2009, 48, 659-666.	2.9	119
36	Emergence of HIV-1 Drug Resistance in Previously Untreated Patients Initiating Combination Antiretroviral Treatment<subtitle>A Comparison of Different Regimen Types</subtitle>. Archives of Internal Medicine, 2007, 167, 1782.	4.3	116

#	Article	IF	Citations
37	Effect of Mutation and Genetic Background on Drug Resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2012, 56, 3047-3053.	1.4	115
38	Reducing Tuberculosis Incidence by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy in an Area of Low Tuberculosis Transmission. Clinical Infectious Diseases, 2007, 44, 94-102.	2.9	114
39	Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared. PLoS Medicine, 2008, 5, e148.	3.9	113
40	Tenofovir Use is associated with a Reduction in Calculated Glomerular Filtration Rates in the Swiss HIV Cohort Study. Antiviral Therapy, 2007, 12, 1165-1174.	0.6	109
41	Variable Impact on Mortality of AIDSâ€Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDSâ€Defining Conditions Are Created Equal. Clinical Infectious Diseases, 2009, 48, 1138-1151.	2.9	108
42	Phylogenetic Approach Reveals That Virus Genotype Largely Determines HIV Set-Point Viral Load. PLoS Pathogens, 2010, 6, e1001123.	2.1	108
43	High colonization rates of extended-spectrum Î²-lactamase (ESBL)-producing Escherichia coliin Swiss Travellers to South Asiaâ€“ a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors. BMC Infectious Diseases, 2014, 14, 528.	1.3	108
44	Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. Aids, 2002, 16, 1967-1969.	1.0	107
45	Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 Ã— 106/l. Aids, 2002, 16, 1371-1381.	1.0	105
46	Modeling the Influence ofAPOC3, APOE,andTNFPolymorphisms on the Risk of Antiretroviral Therapyâ€“Associated Lipid Disorders. Journal of Infectious Diseases, 2005, 191, 1419-1426.	1.9	105
47	ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenetics and Genomics, 2010, 20, 217-230.	0.7	104
48	Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection. Journal of Virology, 2006, 80, 11094-11104.	1.5	103
49	Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection. The Cochrane Library, 2015, 2015, CD006150.	1.5	102
50	Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European caseâ€“control study using centralized ultrasensitive 454 pyrosequencing. Journal of Antimicrobial Chemotherapy, 2015, 70, 930-940.	1.3	102
51	HAART in HIV-infected patients: restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia. Aids, 1999, 13, 1857-1862.	1.0	101
52	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 2017, 66, 297-303.	1.8	101
53	Self-Reported Non-Adherence to Antiretroviral Therapy Repeatedly assessed by Two Questions Predicts Treatment Failure in Virologically Suppressed Patients. Antiviral Therapy, 2008, 13, 77-86.	0.6	100
54	Is It Safe to Discontinue PrimaryPneumocystis jiroveciPneumonia Prophylaxis in Patients with Virologically Suppressed HIV Infection and a CD4 Cell Count <200 Cells/Î¼L?. Clinical Infectious Diseases, 2010, 51, 611-619.	2.9	96

#	Article	IF	Citations
55	Longâ€Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Metaâ€Analysis of Placeboâ€Controlled Trials. Clinical Infectious Diseases, 2010, 50, 473-480.	2.9	96
56	Durability and Outcome of Initial Antiretroviral Treatments Received during 2000â€“2005 by Patients in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2008, 197, 1685-1694.	1.9	95
57	Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 2005, 10, 585-591.	0.6	95
58	Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country. Journal of Clinical Microbiology, 2016, 54, 1862-1870.	1.8	94
59	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count â‰¥200 Cells/ÂµL in the Postâ€“Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
60	Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 197-203.	0.9	91
61	Adverse events of raltegravir and dolutegravir. Aids, 2017, 31, 1853-1858.	1.0	91
62	TheHCP5Singleâ€Nucleotide Polymorphism: A Simple Screening Tool for Prediction of Hypersensitivity Reaction to Abacavir. Journal of Infectious Diseases, 2008, 198, 864-867.	1.9	90
63	Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study. Journal of Infectious Diseases, 2011, 203, 246-257.	1.9	89
64	Tracking a Tuberculosis Outbreak Over 21 Years: Strain-Specific Single-Nucleotide Polymorphism Typing Combined With Targeted Whole-Genome Sequencing. Journal of Infectious Diseases, 2015, 211, 1306-1316.	1.9	82
65	Hepatitis C virus transmission among human immunodeficiency virusâ€infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. Hepatology, 2016, 64, 1856-1869.	3.6	82
66	Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania. Aids, 2017, 31, 61-70.	1.0	80
67	Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. Aids, 2003, 17, F33-F37.	1.0	78
68	HIV Infection Disrupts the Sympatric Hostâ€“Pathogen Relationship in Human Tuberculosis. PLoS Genetics, 2013, 9, e1003318.	1.5	78
69	Systemic inflammatory reaction after starting highly active antiretroviral therapy in AIDS patients treated for extrapulmonary tuberculosis. American Journal of Medicine, 1999, 106, 371-372.	0.6	77
70	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study. Aids, 2003, 17, 2237-2244.	1.0	76
71	Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. Aids, 2000, 14, 243-249.	1.0	75
72	Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2014, 58, 285-294.	2.9	75

#	Article	IF	Citations
73	Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy. Pharmacogenetics and Genomics, 2007, 17, 755-764.	0.7	74
74	Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenetics and Genomics, 2005, 15, 599-608.	0.7	73
75	Randomized, Doubleâ€Blind Comparative Trial of Subunit and Virosomal Influenza Vaccines for Immunocompromised Patients. Clinical Infectious Diseases, 2009, 48, 1402-1412.	2.9	72
76	The HIV care cascade in Switzerland. Aids, 2015, 29, 2509-2515.	1.0	72
77	Tenofovir use is Associated with an Increase in Serum Alkaline Phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1077-1082.	0.6	71
78	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
79	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). International Journal of Epidemiology, 2022, 51, 33-34j.	0.9	69
80	Hypogonadism in HIV-1-Infected Men is common and does not resolve during antiretroviral therapy. Antiviral Therapy, 2007, 12, 261-266.	0.6	69
81	Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir. Aids, 2012, 26, 567-575.	1.0	68
82	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	1.3	68
83	Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality. Open Forum Infectious Diseases, 2015, 2, ofv046.	0.4	68
84	Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis. Lancet, The, 2000, 355, 2217-2218.	6.3	67
85	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2013, 208, 1454-1458.	1.9	67
86	Prevalence of Unsafe Sexual Behavior Among HIV-Infected Individuals: The Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 494-499.	0.9	66
87	Orosomucoid (Î±1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clinical Pharmacology and Therapeutics, 2006, 80, 307-318.	2.3	66
88	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. Annals of Internal Medicine, 2021, 174, 758-767.	2.0	66
89	Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. Aids, 2008, 22, 1019-1028.	1.0	64
90	A sequential Cox approach for estimating the causal effect of treatment in the presence of timeâ€dependent confounding applied to data from the Swiss HIV Cohort Study. Statistics in Medicine, 2010, 29, 2757-2768.	0.8	61

#	Article	IF	Citations
91	Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. Journal of Infectious Diseases, 2015, 212, 28-38.	1.9	61
92	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. Hepatology, 2009, 50, 1017-1029.	3.6	60
93	HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study. Clinical Infectious Diseases, 2016, 62, 115-122.	2.9	60
94	Infrequent Transmission of HIV-1 Drug-Resistant Variants. Antiviral Therapy, 2004, 9, 375-384.	0.6	59
95	Impact of Antiretroviral Therapy on Tuberculosis Incidence Among HIV-Positive Patients in High-Income Countries. Clinical Infectious Diseases, 2012, 54, 1364-1372.	2.9	58
96	Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality. Aids, 2015, 29, 2195-2200.	1.0	58
97	Estimating the net contribution of interleukinâ€28B variation to spontaneous hepatitis C virus clearance. Hepatology, 2011, 53, 1446-1454.	3.6	56
98	Emergence of Klebsiella pneumoniae co-producing NDM-1, OXA-48, CTX-M-15, CMY-16, QnrA and ArmA in Switzerland. International Journal of Antimicrobial Agents, 2014, 44, 260-262.	1.1	56
99	Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. , 2006, , CD006150.		53
100	Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study. Lancet HIV,the, 2016, 3, e120-e131.	2.1	53
101	Incidence and risk factors for hypertension among HIV patients in rural Tanzania â€“ A prospective cohort study. PLoS ONE, 2017, 12, e0172089.	1.1	53
102	Stable virulence levels in the HIV epidemic of Switzerland over two decades. Aids, 2006, 20, 889-894.	1.0	52
103	Reasons for late presentation to HIV care in Switzerland. Journal of the International AIDS Society, 2015, 18, 20317.	1.2	52
104	Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study. Lancet HIV,the, 2015, 2, e335-e343.	2.1	52
105	Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis. Clinical Infectious Diseases, 2016, 62, 1310-1317.	2.9	52
106	Survival in HIV infection: do sex and category of transmission matter?. Aids, 1994, 8, 1307-1313.	1.0	49
107	Occurrence, risk factors, diagnosis and treatment of syphilis in the prospective observational Swiss HIV Cohort Study. Aids, 2010, 24, 1907-1916.	1.0	49
108	Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1659-1666.	1.8	49

#	Article	IF	Citations
109	Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study. PLoS ONE, 2013, 8, e77691.	1.1	49
110	Late Presentation of HIV-Infected Individuals. Antiviral Therapy, 2007, 12, 841-851.	0.6	49
111	Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons. Aids, 2008, 22, 767-775.	1.0	48
112	Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antiviral Therapy, 2007, 12, 1165-73.	0.6	47
113	Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study. BMJ: British Medical Journal, 2004, 328, 15-0.	2.4	46
114	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. Blood, 2004, 104, 1784-1792.	0.6	46
115	CD4⁺T Cell Count Recovery in HIV Type 1â€“Infected Patients Is Independent of Class of Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 47, 1093-1101.	2.9	46
116	Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut, 2010, 59, 1252-1258.	6.1	46
117	Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection: a meta-analysis of randomised controlled trials. BMC Infectious Diseases, 2005, 5, 101.	1.3	45
118	In Vitro Activity of Fosfomycin Alone and in Combination with Ceftriaxone or Azithromycin against Clinical Neisseria gonorrhoeae Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 1605-1611.	1.4	45
119	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 2009, 14, 349-357.	0.6	45
120	Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study. Clinical Infectious Diseases, 2017, 65, 1316-1326.	2.9	44
121	Longâ€Term Trends of HIV Type 1 Drug Resistance Prevalence among Antiretroviral Treatmentâ€“Experienced Patients in Switzerland. Clinical Infectious Diseases, 2009, 48, 979-987.	2.9	43
122	Chronic Hepatitis C in HIV-Infected Patients: Low Eligibility and Applicability of Therapy With Pegylated Interferon-?? Plus Ribavirin. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 38, 238-240.	0.9	41
123	Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. Aids, 2011, 25, 2149-2155.	1.0	41
124	Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection. Journal of Clinical Microbiology, 2012, 50, 388-395.	1.8	41
125	Virological Outcome and Management of Persistent Low-Level Viraemia in HIV-1-Infected Patients: 11 Years of the Swiss HIV Cohort Study. Antiviral Therapy, 2015, 20, 165-175.	0.6	41
126	Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitorâ€“Based Combination Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 568-577.	0.9	41

#	Article	IF	Citations
127	Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study. Aids, 2002, 16, 747-755.	1.0	40
128	Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Aids, 2009, 23, 2199-2208.	1.0	40
129	Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy The Swiss HIV Cohort Study. Aids, 2001, 15, 1793-1800.	1.0	39
130	Contribution of Genome-Wide Significant Single-Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals. Circulation: Cardiovascular Genetics, 2009, 2, 621-628.	5.1	38
131	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. Journal of the International AIDS Society, 2017, 20, 21327.	1.2	38
132	Effect of tenofovir on renal glomerular and tubular function. Aids, 2007, 21, 1483-1485.	1.0	37
133	Dog Bite Injuries: Primary and Secondary Emergency Department Presentationsâ€"A Retrospective Cohort Study. Scientific World Journal, The, 2013, 2013, 1-6.	0.8	37
134	The IFNL3/4 Î"G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. Aids, 2014, 28, 1885-1889.	1.0	37
135	Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Aids, 2009, 23, 2485-2495.	1.0	36
136	Privacy-preserving genomic testing in the clinic: a model using HIV treatment. Genetics in Medicine, 2016, 18, 814-822.	1.1	36
137	Factors Associated with the Emergence of K65R in Patients with HIVâ€1 Infection Treated with Combination Antiretroviral Therapy Containing Tenofovir. Clinical Infectious Diseases, 2008, 46, 1299-1309.	2.9	35
138	Origin of Minority Drug-Resistant HIV-1 Variants in Primary HIV-1 Infection. Journal of Infectious Diseases, 2013, 208, 1102-1112.	1.9	35
139	Increases in Condomless Sex in the Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2015, 2, ofv077-ofv077.	0.4	35
140	Adverse Events to Antiretrovirals in the Swiss HIV Cohort Study: Effect on Mortality and Treatment Modification. Antiviral Therapy, 2007, 12, 1157-1164.	0.6	35
141	Eligibility for and Outcome of Hepatitis C Treatment of HIV-Coinfected Individuals in Clinical Practice: The Swiss HIV Cohort Study. Antiviral Therapy, 2006, 11, 131-142.	0.6	35
142	Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. Aids, 2011, 25, 441-451.	1.0	34
143	Co-Trimoxazole Prophylaxis Is Associated with Reduced Risk of Incident Tuberculosis in Participants in the Swiss HIV Cohort Study. Antimicrobial Agents and Chemotherapy, 2014, 58, 2363-2368.	1.4	34
144	Characterization of Neisseria gonorrhoeaeisolates detected in Switzerland (1998â€"2012): emergence of multidrug-resistant clones less susceptible to cephalosporins. BMC Infectious Diseases, 2014, 14, 106.	1.3	34

#	Article	IF	Citations
145	Prognostic factors for advancedâ€stage human immunodeficiency virusâ€associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multiâ€institutional retrospective study. Cancer, 2015, 121, 423-431.	2.0	34
146	A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Clinical Nephrology, 2012, 77, 311-320.	0.4	34
147	Herpes simplex virus hepatitis 4 years after liver transplantation. Journal of Gastroenterology, 2003, 38, 1005-1008.	2.3	33
148	Burden of serious fungal infections in Tanzania. Mycoses, 2015, 58, 70-79.	1.8	33
149	Multiplex Real-Time PCR Assay with High-Resolution Melting Analysis for Characterization of Antimicrobial Resistance in Neisseria gonorrhoeae. Journal of Clinical Microbiology, 2016, 54, 2074-2081.	1.8	33
150	Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatmentâ€“Naive Individuals Starting Modern Therapy Combinations. Clinical Infectious Diseases, 2012, 54, 131-140.	2.9	32
151	Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection. Archives of Internal Medicine, 2012, 172, 1313.	4.3	31
152	Emergence of Extensively Drug-Resistant Haemophilus parainfluenzae in Switzerland. Antimicrobial Agents and Chemotherapy, 2013, 57, 2867-2869.	1.4	31
153	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. Swiss Medical Weekly, 2016, 146, w14348.	0.8	31
154	Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: A Single Center Study of Epidemiologic Migration-Specific and Clinical Features. AIDS Patient Care and STDs, 2004, 18, 665-675.	1.1	30
155	Short- and long-term mortality and causes of death in HIV/tuberculosis patients in Europe. European Respiratory Journal, 2014, 43, 166-177.	3.1	30
156	The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients. Aids, 2004, 18, 1521-1527.	1.0	29
157	Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. Aids, 2005, 19, 1987-1994.	1.0	29
158	Longer Term Clinical and Virological Outcome of Sub-Saharan African Participants on Antiretroviral Treatment in the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 79-85.	0.9	29
159	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS ONE, 2017, 12, e0180983.	1.1	29
160	Refining Abacavir Hypersensitivity Diagnoses using a Structured Clinical Assessment and Genetic Testing in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 1019-1028.	0.6	29
161	Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. Aids, 2000, 14, 1409-1412.	1.0	28
162	HLAâ€Bw4Homozygosity Is Associated with an Impaired CD4 T Cell Recovery after Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2008, 46, 1921-1925.	2.9	28

#	Article	IF	Citations
163	Improved sensitivity of an interferon-gamma release assay (T-SPOT.TBâ„¢) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-Infection. BMC Infectious Diseases, 2011, 11, 319.	1.3	28
164	Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae upon Traveling to India. Frontiers in Microbiology, 2016, 7, 1069.	1.5	28
165	Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antiviral Therapy, 2008, 13, 77-85.	0.6	28
166	Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania. Swiss Medical Weekly, 2017, 147, w14485.	0.8	27
167	Late presentation of HIV-infected individuals. Antiviral Therapy, 2007, 12, 841-51.	0.6	27
168	CD4⁺ T-Cell Count Increase in HIV-1-Infected Patients with Suppressed Viral Load Within 1 year after start of antiretroviral therapy. Antiviral Therapy, 2007, 12, 889-898.	0.6	27
169	Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study. Aids, 2001, 15, 501-507.	1.0	26
170	Impact of Single Nucleotide Polymorphisms and of Clinical Risk Factors on Newâ€Onset Diabetes Mellitus in HIVâ€Infected Individuals. Clinical Infectious Diseases, 2010, 51, 1090-1098.	2.9	26
171	Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 2013, 68, 207-213.	2.7	26
172	Treatment and Prognosis of AIDS-Related Lymphoma in the Era of Highly Active Antiretroviral Therapy: Findings from the Swiss HIV Cohort Study. Antiviral Therapy, 2007, 12, 931-940.	0.6	26
173	Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. Pharmacogenetics and Genomics, 2013, 23, 9-18.	0.7	25
174	Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition. BMC Infectious Diseases, 2011, 11, 98.	1.3	24
175	The Prevalence of Erectile Dysfunction and Its Association with Antiretroviral Therapy in HIV-Infected Men: The Swiss HIV Cohort Study. Antiviral Therapy, 2013, 18, 337-344.	0.6	24
176	Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)â€“Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clinical Infectious Diseases, 2018, 66, 1099-1108.	2.9	24
177	Update of the Swiss guidelines on post-treatment Lyme disease syndrome. Swiss Medical Weekly, 2016, 146, w14353.	0.8	24
178	Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. Antiviral Therapy, 2009, 14, 349-57.	0.6	24
179	HIV-1 p24 May Persist During Long-Term Highly Active Antiretroviral Therapy, Increases Little During Short Treatment Breaks, and Its Rebound After Treatment Stop Correlates With CD4+ T Cell Loss. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 40, 250-256.	0.9	23
180	Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, 135-142.	0.9	23

#	Article	IF	Citations
181	A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS ONE, 2015, 10, e0123275.	1.1	23
182	Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. PLoS ONE, 2016, 11, e0164320.	1.1	23
183	Predictors of Virological Failure and Time to Viral Suppression of First-Line Integrase Inhibitorâ€"Based Antiretroviral Treatment. Clinical Infectious Diseases, 2021, 73, e2134-e2141.	2.9	23
184	Progressive multifocal leukoencephalopathy in common variable immunodeficiency: mitigated course under mirtazapine and mefloquine. Journal of NeuroVirology, 2015, 21, 694-701.	1.0	22
185	Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel Medicine and Infectious Disease, 2015, 13, 192-196.	1.5	22
186	Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. International Journal of Epidemiology, 2017, 46, dyw211.	0.9	22
187	CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART. Medicine (United States), 2016, 95, e5094.	0.4	22
188	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. Journal of Infectious Diseases, 2020, 222, 637-645.	1.9	22
189	Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania. Tropical Medicine and International Health, 2010, 15, 567-573.	1.0	21
190	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. PLoS ONE, 2011, 6, e27903.	1.1	21
191	Increased risk of wasting syndrome in HIV-infected travellers: prospective multicentre study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001, 95, 484-486.	0.7	20
192	Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma. Ophthalmology, 2003, 110, 432-436.	2.5	20
193	Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients. Aids, 2014, 28, 2231-2239.	1.0	20
194	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. Open Forum Infectious Diseases, 2015, 2, ofv026.	0.4	20
195	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
196	Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification. Antiviral Therapy, 2007, 12, 1157-64.	0.6	20
197	Association of syncytium-inducing phenotype of HIV-1 with CD4 cell count, viral load and sociodemographic characteristics. Aids, 1998, 12, 1341-1346.	1.0	19
198	Are Plasma Levels Valid Surrogates for Cellular Concentrations of Antiretroviral Drugs in HIV-infected Patients?. Therapeutic Drug Monitoring, 2006, 28, 332-338.	1.0	19

#	Article	IF	Citations
199	The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients. PLoS Computational Biology, 2013, 9, e1003203.	1.5	19
200	Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America. PLoS ONE, 2015, 10, e0145380.	1.1	19
201	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International Journal of Antimicrobial Agents, 2017, 50, 453-460.	1.1	19
202	Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 205-213.	0.9	19
203	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. Open Forum Infectious Diseases, 2016, 3, ofw162.	0.4	18
204	Prospective assessment of loss to followâ€up: incidence and associated factors in a cohort of HIVâ€positive adults in rural Tanzania. Journal of the International AIDS Society, 2020, 23, e25460.	1.2	18
205	Impact of Previous Virological Treatment Failures and Adherence on the Outcome of Antiretroviral Therapy in 2007. PLoS ONE, 2009, 4, e8275.	1.1	18
206	Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 53, 464-471.	0.9	17
207	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. International Journal of Infectious Diseases, 2016, 46, 8-10.	1.5	17
208	Development and Validation of Decision Rules to Guide Frequency of Monitoring CD4 Cell Count in HIV-1 Infection before Starting Antiretroviral Therapy. PLoS ONE, 2011, 6, e18578.	1.1	16
209	Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens. PLoS ONE, 2012, 7, e50307.	1.1	16
210	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. ELife, 2017, 6, .	2.8	16
211	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	1.7	16
212	Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2021, 8, ofab032.	0.4	16
213	Prevalence and Clinical Significance of Splenomegaly in Asymptomatic Human Immunodeficiency Virus Type 1-Infected Adults. Clinical Infectious Diseases, 2000, 30, 943-945.	2.9	15
214	Plasma leptin levels in men are not related to the development of lipoatrophy during antiretroviral therapy. Aids, 2005, 19, 1837-1842.	1.0	15
215	Yellow fever vaccination in HIV-infected patients. HIV Therapy, 2010, 4, 17-26.	0.6	15
216	Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients. PLoS ONE, 2012, 7, e37983.	1.1	15

#	Article	IF	Citations
217	Genotypic Resistance Tests Sequences Reveal the Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Scientific Reports, 2016, 6, 27580.	1.6	15
218	Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. Open Forum Infectious Diseases, 2016, 3, ofw022.	0.4	15
219	Prevalence and management of drugâ€“drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. HIV Medicine, 2020, 21, 53-63.	1.0	15
220	Low Current and Nadir CD4⁺ T-Cell Counts are Associated with Higher Hepatitis C virus RNA Levels in the Swiss HIV Cohort Study. Antiviral Therapy, 2008, 13, 455-460.	0.6	15
221	Low Incidence of Communityâ€Acquired Pneumonia among Human Immunodeficiency Virusâ€“Infected Patients after Interruption ofPneumocystis cariniiPneumonia Prophylaxis. Clinical Infectious Diseases, 2003, 36, 917-921.	2.9	14
222	Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. Aids, 2004, 18, 2213-2215.	1.0	14
223	Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy. Journal of Clinical Epidemiology, 2009, 62, 632-641.	2.4	14
224	The J-Curve in HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 302-309.	0.9	14
225	Gradual in vitro Evolution of Cefepime Resistance in an ST131 Escherichia coli Strain Expressing a Plasmid-Encoded CMY-2 Î²-Lactamase. Frontiers in Microbiology, 2019, 10, 1311.	1.5	14
226	Cytotoxic HIV-1 p55gag-specific CD4+ T cells produce HIV-inhibitory cytokines and chemokines. Journal of Clinical Immunology, 2002, 22, 253-262.	2.0	13
227	Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection. Rheumatology, 2010, 49, 1991-1993.	0.9	13
228	Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?. Aids, 2011, 25, 876-878.	1.0	13
229	Shortâ€course amphotericin B in addition to sertraline and fluconazole for treatment of HIVâ€associated cryptococcal meningitis in rural Tanzania. Mycoses, 2019, 62, 1127-1132.	1.8	13
230	Emulating a trial of joint dynamic strategies: An application to monitoring and treatment of HIVâ€positive individuals. Statistics in Medicine, 2019, 38, 2428-2446.	0.8	13
231	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 10-17.	0.9	13
232	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunctionâ€”A Prospective Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 227-232.	0.9	13
233	Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia. Aids, 2004, 18, 2047-2053.	1.0	12
234	Specific Immunotherapy in a Pollen-Allergic Patient With Human Immunodeficiency Virus Infection. World Allergy Organization Journal, 2009, 2, 57-58.	1.6	12

#	Article	IF	Citations
235	Opportunistic infections: an update. Journal of HIV Therapy, 2002, 7, 2-7.	0.6	12
236	Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers. Expert Opinion on Pharmacotherapy, 2005, 6, 891-913.	0.9	11
237	No Longitudinal Mitochondrial DNA Sequence Changes in HIV-infected Individuals With and Without Lipoatrophy. Journal of Infectious Diseases, 2011, 203, 620-624.	1.9	11
238	Changes in Biomarkers of Liver Disease during Successful Combination Antiretroviral Therapy in HIVâ€“HCV-Coinfected Individuals. Antiviral Therapy, 2014, 19, 149-159.	0.6	11
239	Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression. Journal of Antimicrobial Chemotherapy, 2017, 72, 2069-2074.	1.3	11
240	Intestinal colonisation with extended-spectrum cephalosporin-resistant Enterobacteriaceae in different populations in Switzerland: prevalence, risk factors and molecular features. Journal of Global Antimicrobial Resistance, 2018, 12, 17-19.	0.9	11
241	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. Journal of Clinical Medicine, 2021, 10, 295.	1.0	11
242	CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy. Antiviral Therapy, 2007, 12, 889-97.	0.6	11
243	Long-Term Virological Response to Multiple Sequential Regimens of Highly Active Antiretroviral Therapy for HIV Infection. Antiviral Therapy, 2004, 9, 263-274.	0.6	11
244	TB Meningitis in HIV-Positive Patients in Europe and Argentina: Clinical Outcome and Factors Associated with Mortality. BioMed Research International, 2013, 2013, 1-9.	0.9	10
245	Chameleons everywhere. BMJ Case Reports, 2014, 2014, bcr2014205608-bcr2014205608.	0.2	10
246	InÂvitro susceptibility of Aerococcus urinae isolates to antibiotics used for uncomplicated urinary tract infection. Journal of Infection, 2015, 71, 395-397.	1.7	10
247	Bactericidal activity of penicillin, ceftriaxone, gentamicin and daptomycin alone and in combination against Aerococcus urinae. International Journal of Antimicrobial Agents, 2016, 48, 271-276.	1.1	10
248	Comparison of dynamic monitoring strategies based on CD4 cell counts in virally suppressed, HIV-positive individuals on combination antiretroviral therapy in high-income countries: a prospective, observational study. Lancet HIV,the, 2017, 4, e251-e259.	2.1	10
249	Awareness and management of elevated blood pressure among human immunodeficiency virusâ€“infected adults receiving antiretroviral therapy in urban Zambia: a call to action. Global Health Action, 2017, 10, 1359923.	0.7	10
250	Emergence of Drug Resistance in the Swiss HIV Cohort Study Under Potent Antiretroviral Therapy Is Observed in Socially Disadvantaged Patients. Clinical Infectious Diseases, 2020, 70, 297-303.	2.9	10
251	Intestinal colonisation with extended-spectrum cephalosporin- and colistin-resistant Enterobacteriaceae in HIV-positive individuals in Switzerland: molecular features and risk factors. International Journal of Antimicrobial Agents, 2017, 49, 519-521.	1.1	9
252	First two cases of severe multifocal infections caused by Klebsiella pneumoniae in Switzerland: characterization of an atypical non-K1/K2-serotype strain causing liver abscess and endocarditis. Journal of Global Antimicrobial Resistance, 2017, 10, 165-170.	0.9	9

#	Article	IF	Citations
253	Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania. Open Forum Infectious Diseases, 2018, 5, ofy072.	0.4	9
254	IL-4 polymorphism influences susceptibility to Pneumocystis jirovecii pneumonia in HIV-positive patients. Aids, 2019, 33, 1719-1727.	1.0	9
255	Is real time PCR preferable to the direct immunofluorescence in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected patients?. BMC Research Notes, 2020, 13, 235.	0.6	9
256	Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. Journal of Extracellular Vesicles, 2021, 10, e12046.	5.5	9
257	Sexually transmitted infections in HIV-infected people in Switzerland: cross-sectional study. PeerJ, 2014, 2, e537.	0.9	9
258	In vitro activity of clinically implemented Î²-lactams against Aerococcus urinae: presence of non-susceptible isolates in Switzerland. New Microbiologica, 2014, 37, 563-6.	0.1	9
259	Ecological Study of the Predictors of Successful Management of Dyslipidemia in HIV-Infected Patients on ART: the Swiss HIV Cohort Study. HIV Clinical Trials, 2007, 8, 77-85.	2.0	8
260	Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America. Journal of the International AIDS Society, 2014, 17, 19505.	1.2	8
261	Dynamic Models for Estimating the Effect of HAART on CD4 in Observational Studies: Application to the Aquitaine Cohort and the Swiss HIV Cohort Study. Biometrics, 2017, 73, 294-304.	0.8	8
262	Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapyâ€"a prospective multi-centre pilot study1. Journal of Travel Medicine, 2020, 27, .	1.4	8
263	Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE. Clinical Infectious Diseases, 2021, 73, 195-202.	2.9	8
264	The influence of human genetic variation on Epsteinâ€"Barr virus sequence diversity. Scientific Reports, 2021, 11, 4586.	1.6	8
265	No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100Âcells/ÂµL. Journal of the International AIDS Society, 2021, 24, e25726.	1.2	8
266	Does tenofovir influence efavirenz pharmacokinetics?. Antiviral Therapy, 2007, 12, 115-8.	0.6	8
267	Chronic Watery Diarrhea Due to Co-Infection with Cryptosporidium spp and Cyclospora cayetanensis in a Swiss AIDS Patient Traveling in Thailand. Journal of Travel Medicine, 2006, 8, 143-145.	1.4	7
268	Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Aids, 2007, 21, 2201-2207.	1.0	7
269	Predictors of CD4+ T-Cell Counts of HIV Type 1â€"Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
270	Contribution of Genetic Background and Data Collection on Adverse Events of Antiâ€"human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate. Clinical Infectious Diseases, 2019, 70, 890-897.	2.9	7

#	Article	IF	Citations
271	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
272	HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens. Frontiers in Immunology, 2021, 12, 620622.	2.2	7
273	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. Aids, 2022, Publish Ahead of Print, .	1.0	7
274	A case of voluntary intoxication with efavirenz and lamivudine. Aids, 2006, 20, 1352-1354.	1.0	6
275	Opportunistic Diseases During HIV Infectionâ€"Things Arenâ€²t What They Used to Be, or Are They?. Journal of Infectious Diseases, 2016, 214, 830-831.	1.9	6
276	Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. Aids, 2016, 30, 1923-1933.	1.0	6
277	Interferon lambda 3/4 polymorphisms are associated with AIDS-related Kaposi's sarcoma. Aids, 2018, 32, 2759-2765.	1.0	6
278	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infectious Diseases, 2019, 19, 834.	1.3	6
279	Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biology, 2020, 18, e3000963.	2.6	6
280	Sustained virological response to a raltegravir-containing salvage therapy in an HIV-2-infected patient. Aids, 2011, 25, 2306-2308.	1.0	5
281	Smartphone App and Carbon Monoxide Self-Monitoring Support for Smoking Cessation: A Randomized Controlled Trial Nested into the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, e8-e11.	0.9	5
282	Increasing Frequency and Transmission of HIV-1 Non-B Subtypes Among Men Who Have Sex With Men in the Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 306-316.	1.9	5
283	Imaging patterns of Pneumocystis jirovecii pneumonia in HIV-positive and renal transplant patients â€“ a multicentre study. Swiss Medical Weekly, 2019, 149, w20130.	0.8	5
284	Failure to return pillbox is a predictor of being lost to followâ€up among people living with HIV on antiretroviral therapy in rural Tanzania. HIV Medicine, 2022, 23, 661-672.	1.0	5
285	Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Antiviral Therapy, 2009, 14, 953-964.	0.6	4
286	AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be. Journal of the International AIDS Society, 2014, 17, 19621.	1.2	4
287	Virologic and Immunologic Responses in Treatment-Naive Patients to Ritonavir-Boosted Atazanavir or Efavirenz With a Common Backbone. HIV Clinical Trials, 2014, 15, 92-103.	2.0	4
288	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4

#	Article	IF	Citations
289	Fewer pills do not mean fewer drugâ€“drug interactions. Aids, 2018, 32, 676-678.	1.0	4
290	Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy. Open Forum Infectious Diseases, 2020, 7, ofz551.	0.4	4
291	Importance of critical care staffing and standard intensive care therapy in the COVID-19 era: a descriptive study of the first epidemic wave at a Swiss tertiary intensive care unit. Swiss Medical Weekly, 2021, 151, w20529.	0.8	4
292	How do healthcare providers construe patient complexity? A qualitative study of multimorbidity in HIV outpatient clinical practice. BMJ Open, 2021, 11, e051013.	0.8	4
293	Decreasing Incidence and Determinants of Bacterial Pneumonia in People With HIV: The Swiss HIV Cohort Study. Journal of Infectious Diseases, 2022, 225, 1592-1600.	1.9	4
294	Management of opportunistic infection prophylaxis in the highly active antiretroviral therapy era. Current Infectious Disease Reports, 2002, 4, 161-174.	1.3	3
295	Fatal Measles Virus Infection After Rituximab-Containing Chemotherapy in a Previously Vaccinated Patient. Open Forum Infectious Diseases, 2018, 5, ofy244.	0.4	3
296	Impact of Latent Tuberculosis on Diabetes. Journal of Infectious Diseases, 2022, 225, 2229-2234.	1.9	3
297	SPHN/PHRT: Forming a Swiss-Wide Infrastructure for Data-Driven Sepsis Research. Studies in Health Technology and Informatics, 2020, 270, 1163-1167.	0.2	3
298	Tenofovir-Containing Nucleoside/Nucleotide-Only Antiretroviral Maintenance Therapy: Decision Making and Virological Outcome. HIV Clinical Trials, 2006, 7, 48-54.	2.0	2
299	Clonal analysis of Aerococcus urinae isolates by using the repetitive extragenic palindromic PCR (rep-PCR). Journal of Infection, 2016, 72, 262-265.	1.7	2
300	Think tuberculosisâ€”but is thinking enough?. Lancet Infectious Diseases, The, 2020, 20, 639-640.	4.6	2
301	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	2.9	2
302	Recognition and management of clinically significant drugâ€“drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2681-2689.	1.3	2
303	Rate of treatment success and associated factors in the program for drug-susceptible tuberculosis in the Forest Region, Republic of Guinea, 2010-2017: A real-world retrospective observational cohort study. International Journal of Infectious Diseases, 2021, 110, 6-14.	1.5	2
304	Reply to Hamlyn et al. Clinical Infectious Diseases, 2007, 44, 1394-1395.	2.9	1
305	The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe. Journal of the International AIDS Society, 2014, 17, 19561.	1.2	1
306	Travellers returning ill from the tropics â€“ a descriptive retrospective study. Tropical Diseases, Travel Medicine and Vaccines, 2016, 2, 6.	0.9	1

#	Article	IF	Citations
307	Distinct Clinical and Laboratory Patterns of Pneumocystis jirovecii Pneumonia in Renal Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2021, 7, 1072.	1.5	1
308	Inhibition of syncytia-inducing (SI) virus by autologous serum from HIV-1-infected individuals. Clinical and Diagnostic Virology, 1996, 6, 127-135.	1.8	0
309	The Role of CFTR and SPINK-1 Mutations in Pancreatic Disorders in HIV-Positive Patients. Aids, 2004, 18, 1971.	1.0	0
310	Risk Factors for Low Immune Recovery Among Participants with CD4+ Counts > 500 cells/mm3 who Achieved Viral Suppression in the Immediate Antiretroviral Treatment (ART) Group in Strategic Timing of Antiretroviral Treatment (START) Trial. Open Forum Infectious Diseases, 2016, 3, .	0.4	0
311	HIV-Infektion. , 2015, , 1-15.		0
312	Title is missing!. , 2020, 18, e3000963.		0
313	Title is missing!. , 2020, 18, e3000963.		0
314	Title is missing!. , 2020, 18, e3000963.		0
315	Title is missing!. , 2020, 18, e3000963.		0
316	Title is missing!. , 2020, 18, e3000963.		0
317	Title is missing!. , 2020, 18, e3000963.		0